|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/23 NovaBay Pharmaceuticals, Inc. 10-Q 9/30/23 95:10M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.87M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
11: R1 Document And Entity Information HTML 79K
12: R2 Condensed Consolidated Balance Sheets (Current HTML 125K
Period Unaudited)
13: R3 Condensed Consolidated Balance Sheets (Current HTML 54K
Period Unaudited) (Parentheticals)
14: R4 Condensed Consolidated Statements of Operations HTML 98K
(Unaudited)
15: R5 Condensed Consolidated Statements of Stockholders' HTML 161K
Equity (Unaudited)
16: R6 Condensed Consolidated Statements of Cash Flows HTML 138K
(Unaudited)
17: R7 Note 1 - Organization HTML 39K
18: R8 Note 2 - Summary of Significant Accounting HTML 144K
Policies
19: R9 Note 3 - Fair Value Measurements HTML 76K
20: R10 Note 4 - Prepaid Expenses and Other Current Assets HTML 38K
21: R11 Note 5 - Inventory HTML 35K
22: R12 Note 6 - Property and Equipment HTML 39K
23: R13 Note 7 - Other Intangible Assets HTML 64K
24: R14 Note 8 - Accrued Liabilities HTML 38K
25: R15 Note 9 - Convertible Note HTML 58K
26: R16 Note 10 - Commitments and Contingencies HTML 57K
27: R17 Note 11 - Warrant Liability HTML 82K
28: R18 Note 12 - Stockholders' Equity HTML 149K
29: R19 Note 13 - Equity-based Compensation HTML 83K
30: R20 Note 14 - Distribution Agreements HTML 45K
31: R21 Note 15 - Employee Benefit Plan HTML 33K
32: R22 Note 16 - Related Party Transactions HTML 47K
33: R23 Note 17 - Segment Reporting HTML 88K
34: R24 Note 18 - Subsequent Events HTML 30K
35: R25 Significant Accounting Policies (Policies) HTML 198K
36: R26 Note 2 - Summary of Significant Accounting HTML 90K
Policies (Tables)
37: R27 Note 3 - Fair Value Measurements (Tables) HTML 71K
38: R28 Note 4 - Prepaid Expenses and Other Current Assets HTML 38K
(Tables)
39: R29 Note 5 - Inventory (Tables) HTML 35K
40: R30 Note 6 - Property and Equipment (Tables) HTML 37K
41: R31 Note 7 - Other Intangible Assets (Tables) HTML 64K
42: R32 Note 8 - Accrued Liabilities (Tables) HTML 37K
43: R33 Note 9 - Convertible Note (Tables) HTML 49K
44: R34 Note 10 - Commitments and Contingencies (Tables) HTML 50K
45: R35 Note 11 - Warrant Liability (Tables) HTML 71K
46: R36 Note 12 - Stockholders' Equity (Tables) HTML 110K
47: R37 Note 13 - Equity-based Compensation (Tables) HTML 73K
48: R38 Note 14 - Distribution Agreements (Tables) HTML 38K
49: R39 Note 16 - Related Party Transactions (Tables) HTML 42K
50: R40 Note 17 - Segment Reporting (Tables) HTML 83K
51: R41 Note 1 - Organization (Details Textual) HTML 30K
52: R42 Note 2 - Summary of Significant Accounting HTML 70K
Policies (Details Textual)
53: R43 Note 2 - Summary of Significant Accounting HTML 35K
Policies - Components of Cash, Cash Equivalents,
and Restricted Cash (Details)
54: R44 Note 2 - Summary of Significant Accounting HTML 41K
Policies - Disaggregation of Revenue (Details)
55: R45 Note 2 - Summary of Significant Accounting HTML 40K
Policies - Revenues and Accounts Receivable from
Major Distribution Partners and Customers
(Details)
56: R46 Note 2 - Summary of Significant Accounting HTML 60K
Policies - Calculation of Basic and Diluted EPS
(Details)
57: R47 Note 2 - Summary of Significant Accounting HTML 36K
Policies - Outstanding Stock Options and Stock
Warrants Excluded from the Diluted Net Loss Per
Share Computation (Details)
58: R48 Note 3 - Fair Value Measurements - Assets and HTML 39K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
59: R49 Note 4 - Prepaid Expenses and Other Current Assets HTML 41K
- Summary of Prepaid Expenses and Other Current
Assets (Details)
60: R50 Note 5 - Inventory - Summary of Inventory HTML 34K
(Details)
61: R51 Note 6 - Property and Equipment (Details Textual) HTML 27K
62: R52 Note 6 - Property and Equipment - Summary of HTML 41K
Property and Equipment (Details)
63: R53 Note 7 - Other Intangible Assets (Details Textual) HTML 34K
64: R54 Note 7 - Other Intangible Assets - Schedule of HTML 50K
Finite-lived Intangible Assets (Details)
65: R55 Note 7 - Other Intangible Assets - Schedule of HTML 38K
Finite-Lived Intangible Assets, Future
Amortization Expense (Details)
66: R56 Note 8 - Accrued Liabilities - Summary of Accrued HTML 39K
Liabilities (Details)
67: R57 Note 9 - Convertible Note (Details Textual) HTML 91K
68: R58 Note 9 - Convertible Note - Key Assumptions of HTML 36K
Combined Embedded Derivative (Details)
69: R59 Note 9 - Convertible Note - Debenture (Details) HTML 37K
70: R60 Note 9 - Convertible Note - Contractual Maturity HTML 35K
(Details)
71: R61 Note 10 - Commitments and Contingencies (Details HTML 28K
Textual)
72: R62 Note 10 - Commitments and Contingencies - Lease HTML 35K
Expense (Details)
73: R63 Note 10 - Commitments and Contingencies - Schedule HTML 46K
of Future Lease Payments (Details)
74: R64 Note 11 - Warrant Liability (Details Textual) HTML 50K
75: R65 Note 11 - Warrant Liability - The Key Assumptions HTML 90K
Used to Value the Warrants (Details)
76: R66 Note 12 - Stockholders' Equity (Details Textual) HTML 271K
77: R67 Note 12 - Stockholders' Equity - The Key HTML 70K
Assumptions Used to Value the Warrants (Details)
78: R68 Note 12 - Stockholders' Equity - Preferred Stock HTML 47K
Assumptions (Details)
79: R69 Note 12 - Stockholders' Equity - Outstanding HTML 37K
Warrants (Details)
80: R70 Note 13 - Equity-based Compensation (Details HTML 87K
Textual)
81: R71 Note 13 - Equity-based Compensation - Stock HTML 76K
Options Outstanding (Details)
82: R72 Note 13 - Equity-based Compensation - HTML 38K
Weighted-average Assumptions Used in Determining
the Value of Options Granted to Employees and
Directors (Details)
83: R73 Note 13 - Equity-based Compensation - Summary of HTML 33K
Stock-based Compensation Expense Included in
Results of Operations (Details)
84: R74 Note 14 - Distribution Agreements (Details HTML 48K
Textual)
85: R75 Note 14 - Distribution Agreements - Changes in HTML 40K
Assets and Liabilities (Details)
86: R76 Note 15 - Employee Benefit Plan (Details Textual) HTML 37K
87: R77 Note 16 - Related Party Transactions (Details HTML 29K
Textual)
88: R78 Note 16 - Related Party Transactions - Related HTML 37K
Party Revenue, Cost of Goods Sold, and Expenses
(Details)
89: R79 Note 17 - Segment Reporting (Details Textual) HTML 27K
90: R80 Note 17 - Segment Reporting - Financial HTML 46K
Information by Segment (Details)
93: XML IDEA XML File -- Filing Summary XML 181K
91: XML XBRL Instance -- nby20230930_10q_htm XML 3.03M
92: EXCEL IDEA Workbook of Financial Report Info XLSX 178K
7: EX-101.CAL XBRL Calculations -- nby-20230930_cal XML 149K
8: EX-101.DEF XBRL Definitions -- nby-20230930_def XML 1.59M
9: EX-101.LAB XBRL Labels -- nby-20230930_lab XML 1.22M
10: EX-101.PRE XBRL Presentations -- nby-20230930_pre XML 1.63M
6: EX-101.SCH XBRL Schema -- nby-20230930 XSD 268K
94: JSON XBRL Instance as JSON Data -- MetaLinks 522± 861K
95: ZIP XBRL Zipped Folder -- 0001437749-23-031256-xbrl Zip 313K
Exhibit 31.2
CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Tommy Law, certify that:
1. I have reviewed this Form 10-Q of NovaBay Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2023
|
/s/ Tommy Law |
|
|
Interim Chief Financial Officer |
|
|
(principal financial officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/9/23 | None on these Dates | ||
| For Period end: | 9/30/23 | |||
| List all Filings | ||||